| Phase 15 trials |
|
Phase 1
|
NCT06357858 |
Jun 2024 → Feb 2025 |
head and neck squamous cell carcinoma, metastatic squamous cell carcinoma |
Case Comprehensive Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT06191978 |
Mar 2024 → Dec 2028 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06177171 |
Feb 2024 → Jan 2028 expected |
ATM-related cancer predisposition, BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, CHEK2-related cancer predisposition +1 |
Varun Monga, MBBS |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04134884 |
Apr 2020 → Jan 2024 |
hormone receptor-positive breast cancer, metastatic malignant neoplasm, triple-negative breast carcinoma |
Kathy Miller |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02998567 |
Jan 2017 → Sep 2026 expected |
non-small cell lung carcinoma |
Royal Marsden NHS Foundation Trust |
Active not recruiting
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT07472322 |
Jul 2026 → May 2031 expected |
cutaneous neuroendocrine carcinoma |
University of Wisconsin, Madison |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06284460 |
Jan → Dec 2025 |
myelodysplastic syndrome, myeloproliferative neoplasm |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT06113289 |
Feb 2024 → Mar 2025 |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT06091267 |
Oct 2023 → May 2026 overdue |
myelodysplastic syndrome |
Otsuka Beijing Research Institute |
Active not recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07710534 |
Sep 2026 → Sep 2031 expected |
acute myeloid leukemia, myelodysplastic syndrome |
Virginia Commonwealth University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06297629 |
Jul 2024 |
disease related to hematopoietic stem cell transplant |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT05201066 |
Feb 2023 → Feb 2028 expected |
chronic myelomonocytic leukemia, myelodysplastic syndrome |
Novartis Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04857645 |
Jun 2021 → Apr 2024 |
acute myeloid leukemia, myelodysplastic syndrome |
Groupe Francophone des Myelodysplasies |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04093570 |
Sep 2019 → Dec 2027 expected |
acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
Taiho Oncology, Inc. |
Enrolling by invitation
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT03306264 |
Feb 2018 → Sep 2021 |
acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
Astex Pharmaceuticals, Inc. |
Completed
|
No outcome recorded
|